Dianthus Therapeutics
DNTH
48 hedge funds and large institutions have $182M invested in Dianthus Therapeutics in 2018 Q2 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
2.44% more ownership
Funds ownership: 0% → 2.44% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
+$47.1M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$31.6M |
| 3 |
CC
Casdin Capital
New York
|
+$28.7M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$21.7M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$11.7M |
Top Sellers
DNTH Hedge Fund Activity: Q2 2018 in Review
48 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2018, worth a combined $182M.
Buyers outnumbered sellers: 48 funds opened new DNTH positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Alphabet Inc, opening a new position worth an estimated $47.1M.
- 48 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $182M of Dianthus Therapeutics stock for Q2 2018.
- 48 funds opened new Dianthus Therapeutics positions in Q2 2018 and 0 closed out, a net change of +48 holders.
- The largest Dianthus Therapeutics buyer in Q2 2018 was Alphabet Inc, an estimated $47.1M added.
Based on aggregated 13F filings for Q2 2018.